Clinical Trial Environmental Impact
CMC Ontology
Data FAIRy Bioassay Annotation
Global Substance Registration System
IDMP Ontology
In Vitro NAM Data Standards
In Vitro Pharmacology
Large Language Models in Life Sciences
NLP Use Case Database
Pharma General Ontology
Social Media Real World Evidence
Current Projects
Delivered Projects
AI / ML
Change Management
CSCS
Data Governance
FAIR
Future Labs Evolution
Microbiome-Mediated Drug Metabolism Database
Quantum Computing
UXLS
Current Communities
Delivered Communities
Delivered Projects and Communities
New Ideas
Username or Email Address
Password
Remember Me
Webinar
This project aims to build a pharmaceutical (CMC) process ontology based on the ISA88/95 framework to standardize laboratory and plant production process recipes to establish standardized definitions, facilitate digital technology transfers, and integration with execution systems.
We know enough about the LLM technology at this time to move it from popular hype into production. We are, however, still at the beginning of this journey. What does biopharma research need to focus on to ensure they are implementing LLMs effectively?
ACMD has made recommendations to reduce barriers to research, using compounds described by the third generation synthetic cannabinoid receptor agonists generic definition. This webinar will cover the background and how the Pistoia Alliance Controlled Substance Compliance and Shipping (CSCS) expert community investigates the potential implications of such proposals.
In this webinar, we look at how data quality affects the performance of LLMs. For this, we assess how LLM-powered AI agents query across three versions of the same gene expression corpus, but with varying degrees of quality
Join us for this inaugural update on the newly formed Strategic Priorities of the Pistoia Alliance, followed by a 30 minutes Q&A with our panelists
Join us to learn more about our IDMP-O initiative. Our newly launched IDMP-O version 1.0 covers all five ISO IDMP standards, enabling a broad range of use cases around substance identification, regulatory processes integration with manufacturing, supply-chain analytics, therapeutic indications, representation of jurisdiction-agnostic medicinal products and pharmacovigilance.
Why is managing change so critical in digital transformation? What are some of the challenges in a successful rollout? How do you manage change effectively when digital transformation is just one of the changes that people are experiencing? What are the key success factors in effective digital transformation?
Most recently both the EU and the US announced new legislation aiming to regulate the development and use of Artificial Intelligence: the EU AI Act and the President Biden Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence. Our panel of experts will discuss how these legal changes may affect research and development in drug discovery.
“Advancing Research: Reducing Animal Models in Experiments” addresses the pressing need to reduce reliance on animal models in scientific research, particularly in light of the FDA Modernization Act 2.0. The event encompasses an overview of the current research environment, exploring innovative alternatives such as virtual control groups, organ-on-a-chip technology, and in-vitro methods.
Liquid biopsies can be used to detect early cancer recurrence, explore therapeutic resistance, and personalize treatment. In this seminar, we will explore three different perspectives to delve into the potential of ctDNA and rare cells in the context of an ever-increasing drive to personalize medicine.
The aim of this study was to make unstructured neuropathological data, located in the NeuroBioBank (NBB), follow FAIR (Findability, Accessibility, Interoperability, and Reusability) principles, and investigate the potential of Large Language Models (LLMs) in wrangling unstructured neuropathological reports.
